Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
复制标题
DOI：
10.1016/j.clinthera.2017.10.016
复制
发表时间：
2017-12-01
影响因子：
3.2
通讯作者：
Goldenberg, Ronald M.
中科院分区：
文献类型：
--
作者：
Goldenberg, Ronald M.
目的：2型糖尿病仍然是一种管理不善的疾病，只有大约一半的2型糖尿病患者符合指南推荐的糖化血红蛋白（HbA（1c））目标。大部分未达到HbA（1c）目标的患者的HbA（1c）
Purpose: Type 2 diabetes remains a poorly managed disease, with only about half of individuals with type 2 diabetes meeting guideline-recommended glycosylated hemoglobin (HbA(1c)) targets. A major proportion of those who have not met HbA(1c) goals have an HbA(1c)